Enhancing the immune response against recurrent ovarian cancer
Official title: Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer
Funded at Roswell Park Cancer Institute Corp · NIH-10892999 · Data updated 2026-11-12
This study is looking at how to boost the immune system's fight against recurrent ovarian cancer by using a special treatment called APL-2, and it's for patients who are dealing with this type of cancer and its related complications.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | August 24, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $618,854 |
| NIH project number | 5R01CA267690-03 |
| Project ID | NIH-10892999 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with recurrent epithelial ovarian cancer who are experiencing persistent malignant effusions.
✕Less likely to help
Patients with early-stage ovarian cancer or those who do not have recurrent disease may not benefit from this research.
What this research studies
This research focuses on improving the immune system's ability to fight recurrent epithelial ovarian cancer by targeting specific components of the immune response. The study aims to understand how certain immune cells, particularly neutrophils, can suppress the body's natural defenses against tumors and how this suppression can be overcome. By using a peptide inhibitor called APL-2, the researchers will conduct a clinical trial to evaluate its effectiveness in enhancing anti-tumor immunity in patients with recurrent ovarian cancer and associated malignant effusions.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for patients with recurrent ovarian cancer.
How similar studies have gone: Previous research has shown promise in targeting immune suppression in tumors, suggesting that this approach could be effective, although the specific use of APL-2 in this context is novel.
Where this research is happening
-
Roswell Park Cancer Institute Corp
Buffalo, United States Active
Researchers
- Principal investigator: Zsiros, Emese — Roswell Park Cancer Institute Corp
- Study coordinator: Zsiros, Emese
Related research
Other NIH-funded projects on the same topics.
-
TAG72 CAR-T therapy for recurrent epithelial ovarian cancer
A targeted CAR-T cell therapy delivered into the abdomen for women with recurrent epithelial ovarian cancer to attack cancer cells expressing TAG72.
-
Liquid biopsy clues: plasma bacteria as early warning for epithelial ovarian cancer
A patient-friendly look at a new approach that uses tiny bacteria signals in blood to help detect ovarian cancer early.
-
Understanding how cancer cells talk to the immune system and how to use that to treat ovarian cancer
This grant studies how aging-like changes in ovarian cancer cells drive harmful signals and tests new ways to block those signals to improve treatment.
-
Targeting the immune system to help treat recurrent ovarian cancer
Aims to test a new approach that blocks a part of the immune system (complement) to boost anticancer immunity in people with recurrent ovarian cancer and fluid buildup.
-
Th17-inducing vaccine plus pembrolizumab for recurrent ovarian cancer
A phase I/II study tests a vaccine that activates Th17 immune cells together with pembrolizumab to help fight recurrent ovarian cancer.
-
CAR T-cell therapy targeting TAG72 for recurrent epithelial ovarian cancer
This trial tries a CAR T‑cell treatment that targets the TAG72 protein for people with recurrent epithelial ovarian cancer, given directly into the abdomen.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.